VIFOR PHARMA EXPANDS EXCLUSIVE LICENSE AGREEMENT FOR THE COMMERCIALISATION OF MIRCERA® IN THE US
(Thomson Reuters ONE) -
Vifor Pharma Ltd. /
VIFOR PHARMA EXPANDS EXCLUSIVE LICENSE AGREEMENT FOR THE COMMERCIALISATION OF
MIRCERA® IN THE US
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* Additional Mircera(®) volume will provide Vifor Pharma with more flexibility
to expand its US ESA business
IN 2015 VIFOR PHARMA (FORMERLY A COMPANY OF GALENICA GROUP) ENTERED INTO AN
EXCLUSIVE LICENSE AGREEMENT WITH ROCHE FOR THE COMMERCIALISATION OF ITS MEDICINE
MIRCERA(®) in the US. MIRCERA(®) IS A LONG-ACTING ESA INDICATED FOR THE
TREATMENT OF ANAEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) IN ADULT
PATIENTS.
Mircera(®) (methoxy polyethylene glycol-epoetin beta) is approved in the US by
the Food and Drug Administration (FDA) and in the European Union by the European
Medicines Agency (EMA) for the treatment of anaemia associated with CKD in adult
patients on dialysis as well as those not on dialysis. Anaemia in CKD is
associated with reduced quality of life and increased cardiovascular disease,
hospitalisations, cognitive impairment and mortality(1). Mircera(®) is a long-
acting erythropoiesis stimulating agent (ESA) for bi-weekly or monthly
treatment. It works like the human protein erythropoietin, to help the body make
more red blood cells, and is used to reduce or avoid the need for red blood cell
transfusion.
Following a successful rollout of Mircera(®) at Fresenius Kidney Care clinics,
there are currently more than 140,000 patients in the United States under
treatment with Mircera(®).
In order to provide Vifor Pharma more flexibility to meet the ESA requirements
of the US nephrology market, Vifor Pharma and Roche have now completed an
agreement giving Vifor Pharma access to additional volume for Mircera(®) for the
US market in order to optimally meet the needs of new and existing partners.
FURTHER INFORMATION
Media Relations Investor Relations
Beatrix Benz Julien Vignot
Head of Global Communications & Public Head of Investor Relations
Affairs Tel.: +41 58 851 66 90
Tel.: +41 58 851 80 16 E-mail: investors(at)viforpharma.com
E-mail: media(at)viforpharma.com
Vifor Pharma Group, formerly Galenica Group, is a global specialty
pharmaceuticals company. It aims to become the global leader in iron deficiency,
nephrology and cardio-renal therapies. The company is the partner of choice for
specialty pharmaceuticals and innovative patient-focused solutions. Vifor Pharma
Group strives to help patients around the world with severe and chronic diseases
lead better, healthier lives. The company develops, manufactures and markets
pharmaceutical products for precision patient care. Vifor Pharma Group holds a
leading position in all its core business activities and consists of the
following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma, a
joint company with Fresenius Medical Care; Relypsa; and OM Pharma. Vifor Pharma
Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange
(SIX Swiss Exchange, VIFN, ISIN: CH0364749348). For more information, please
visit www.viforpharma.com.
About Mircera(® )
Mircera(®) (methoxy polyethylene glycol-epoetin beta) is an erythropoietin
stimulating agent used for the treatment of symptomatic anaemia associated with
chronic kidney disease (CKD) in adult patients. Outside the US, Mircera(®) is
currently marketed worldwide by Roche, except in Japan, where it is marketed by
Chugai.
References
1. J Am Soc Nephrol 23: 1631 - 1634, 2012.
PRESS RELEASE:
http://hugin.info/148637/R/2137111/817893.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Vifor Pharma Ltd. via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 27.09.2017 - 06:57 Uhr
Sprache: Deutsch
News-ID 561406
Anzahl Zeichen: 4626
contact information:
Town:
Glattbrugg
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 285 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"VIFOR PHARMA EXPANDS EXCLUSIVE LICENSE AGREEMENT FOR THE COMMERCIALISATION OF MIRCERA® IN THE US"
steht unter der journalistisch-redaktionellen Verantwortung von
Vifor Pharma Ltd. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
